TY  - JOUR
AU  - Kerec Kos, Mojca
AU  - Miksić, Mirjana
AU  - Jovanović, Marija
AU  - Roškar, Robert
AU  - Grosek, Štefan
AU  - Grabnar, Iztok
PY  - 2020
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3517
AB  - Purpose: The aim of the present study was to develop a population pharmacokinetic model of midazolam, and to evaluate the influence of maturation process and other variability factors in critically ill children with severe acute bronchiolitis, who received a long-term intravenous infusion of midazolam. Methods: In the study were included 49 critically ill children of both genders (from 0 to 130 weeks of age) with severe acute bronchiolitis hospitalised in intensive care units. Nonlinear mixed effects modelling approach was applied for data analyses and simulations. Results: The final model is a two-compartment model that includes the effects of body weight using allometric scaling with fixed exponents and maturation of clearance. For a typical subject, scaled to the adult body weight of 70 kg, population pharmacokinetic values were estimated at 8.52 L/h for clearance (when maturation function was 1), 25.5 L/h for intercompartmental clearance, and 5.71 L and 39.8 L for the volume of the central and peripheral compartment, respectively. Based on the final model, maturation reaches 50% of the adult clearance in 45.9 weeks of postmenstrual age. The influence of gender, ABCB1 genotype and biochemical parameters on midazolam clearance was not detected. Results of simulations indicate the need for reduced dosing in certain groups of patients in order to maintain plasma concentrations of midazolam within recommended values. Conclusions: The developed population pharmacokinetic model can contribute to the dosing optimisation of midazolam, especially in critically ill children as it includes the influence of size and maturation of clearance, which are important parameters for achieving the desired plasma concentrations of midazolam.
PB  - Elsevier
T2  - European Journal of Pharmaceutical Sciences
T1  - Maturation of midazolam clearance in critically ill children with severe bronchiolitis: A population pharmacokinetic analysis
VL  - 141
DO  - 10.1016/j.ejps.2019.105095
ER  - 

@article{
author = "Kerec Kos, Mojca and Miksić, Mirjana and Jovanović, Marija and Roškar, Robert and Grosek, Štefan and Grabnar, Iztok",
year = "2020",
abstract = "Purpose: The aim of the present study was to develop a population pharmacokinetic model of midazolam, and to evaluate the influence of maturation process and other variability factors in critically ill children with severe acute bronchiolitis, who received a long-term intravenous infusion of midazolam. Methods: In the study were included 49 critically ill children of both genders (from 0 to 130 weeks of age) with severe acute bronchiolitis hospitalised in intensive care units. Nonlinear mixed effects modelling approach was applied for data analyses and simulations. Results: The final model is a two-compartment model that includes the effects of body weight using allometric scaling with fixed exponents and maturation of clearance. For a typical subject, scaled to the adult body weight of 70 kg, population pharmacokinetic values were estimated at 8.52 L/h for clearance (when maturation function was 1), 25.5 L/h for intercompartmental clearance, and 5.71 L and 39.8 L for the volume of the central and peripheral compartment, respectively. Based on the final model, maturation reaches 50% of the adult clearance in 45.9 weeks of postmenstrual age. The influence of gender, ABCB1 genotype and biochemical parameters on midazolam clearance was not detected. Results of simulations indicate the need for reduced dosing in certain groups of patients in order to maintain plasma concentrations of midazolam within recommended values. Conclusions: The developed population pharmacokinetic model can contribute to the dosing optimisation of midazolam, especially in critically ill children as it includes the influence of size and maturation of clearance, which are important parameters for achieving the desired plasma concentrations of midazolam.",
publisher = "Elsevier",
journal = "European Journal of Pharmaceutical Sciences",
title = "Maturation of midazolam clearance in critically ill children with severe bronchiolitis: A population pharmacokinetic analysis",
volume = "141",
doi = "10.1016/j.ejps.2019.105095"
}

Kerec Kos, M., Miksić, M., Jovanović, M., Roškar, R., Grosek, Š.,& Grabnar, I.. (2020). Maturation of midazolam clearance in critically ill children with severe bronchiolitis: A population pharmacokinetic analysis. in European Journal of Pharmaceutical Sciences
Elsevier., 141.
https://doi.org/10.1016/j.ejps.2019.105095

Kerec Kos M, Miksić M, Jovanović M, Roškar R, Grosek Š, Grabnar I. Maturation of midazolam clearance in critically ill children with severe bronchiolitis: A population pharmacokinetic analysis. in European Journal of Pharmaceutical Sciences. 2020;141.
doi:10.1016/j.ejps.2019.105095 .

Kerec Kos, Mojca, Miksić, Mirjana, Jovanović, Marija, Roškar, Robert, Grosek, Štefan, Grabnar, Iztok, "Maturation of midazolam clearance in critically ill children with severe bronchiolitis: A population pharmacokinetic analysis" in European Journal of Pharmaceutical Sciences, 141 (2020),
https://doi.org/10.1016/j.ejps.2019.105095 . .

TY  - JOUR
AU  - Golubović, Bojana
AU  - Prostran, Milica
AU  - Miljković, Branislava
AU  - Vučićević, Katarina
AU  - Radivojević, Dragana
AU  - Grabnar, Iztok
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2678
AB  - Immunosuppressive therapy is the cornerstone of successful kidney transplantation. Frequently used immunosuppressives are cyclosporine, tacrolimus, sirolimus and mycophenolic acid. These drugs have narrow therapeutic index and show high pharmacokinetic variability. In order to maintain the balance between efficacy and safety, dosing is based on measured drug concentrations. Proper identification, quantification and understanding the sources of variability in measured concentrations facilitate routine dose adjustment in clinical practice. Classical pharmacokinetic studies have limited use in transplant patients attributable to design with intense sampling in a small, relatively homogenous population, and identification of only single variability factor per study. Population approach is a powerful tool for analysing sparse data, identifying factors that influence drug pharmacokinetics and estimating variability. In this report we reviewed available population pharmacokinetic models for cyclosporine, tacrolimus, sirolimus and mycophenolic acid in adult kidney transplant patients. The major focus was to describe various demographic factors, biochemical parameters, genetic polymorphisms of metabolic enzymes and transporters and drug-drug interactions, which have been identified as an important concern of pharmacokinetic variability in kidney transplant patients.
PB  - Bentham Science Publ Ltd, Sharjah
T2  - Current Medicinal Chemistry
T1  - Population Pharmacokinetic Approach of Immunosuppressive Therapy in Kidney Transplant Patients
VL  - 23
IS  - 19
SP  - 1998
EP  - 2011
DO  - 10.2174/0929867323666151221150214
ER  - 

@article{
author = "Golubović, Bojana and Prostran, Milica and Miljković, Branislava and Vučićević, Katarina and Radivojević, Dragana and Grabnar, Iztok",
year = "2016",
abstract = "Immunosuppressive therapy is the cornerstone of successful kidney transplantation. Frequently used immunosuppressives are cyclosporine, tacrolimus, sirolimus and mycophenolic acid. These drugs have narrow therapeutic index and show high pharmacokinetic variability. In order to maintain the balance between efficacy and safety, dosing is based on measured drug concentrations. Proper identification, quantification and understanding the sources of variability in measured concentrations facilitate routine dose adjustment in clinical practice. Classical pharmacokinetic studies have limited use in transplant patients attributable to design with intense sampling in a small, relatively homogenous population, and identification of only single variability factor per study. Population approach is a powerful tool for analysing sparse data, identifying factors that influence drug pharmacokinetics and estimating variability. In this report we reviewed available population pharmacokinetic models for cyclosporine, tacrolimus, sirolimus and mycophenolic acid in adult kidney transplant patients. The major focus was to describe various demographic factors, biochemical parameters, genetic polymorphisms of metabolic enzymes and transporters and drug-drug interactions, which have been identified as an important concern of pharmacokinetic variability in kidney transplant patients.",
publisher = "Bentham Science Publ Ltd, Sharjah",
journal = "Current Medicinal Chemistry",
title = "Population Pharmacokinetic Approach of Immunosuppressive Therapy in Kidney Transplant Patients",
volume = "23",
number = "19",
pages = "1998-2011",
doi = "10.2174/0929867323666151221150214"
}

Golubović, B., Prostran, M., Miljković, B., Vučićević, K., Radivojević, D.,& Grabnar, I.. (2016). Population Pharmacokinetic Approach of Immunosuppressive Therapy in Kidney Transplant Patients. in Current Medicinal Chemistry
Bentham Science Publ Ltd, Sharjah., 23(19), 1998-2011.
https://doi.org/10.2174/0929867323666151221150214

Golubović B, Prostran M, Miljković B, Vučićević K, Radivojević D, Grabnar I. Population Pharmacokinetic Approach of Immunosuppressive Therapy in Kidney Transplant Patients. in Current Medicinal Chemistry. 2016;23(19):1998-2011.
doi:10.2174/0929867323666151221150214 .

Golubović, Bojana, Prostran, Milica, Miljković, Branislava, Vučićević, Katarina, Radivojević, Dragana, Grabnar, Iztok, "Population Pharmacokinetic Approach of Immunosuppressive Therapy in Kidney Transplant Patients" in Current Medicinal Chemistry, 23, no. 19 (2016):1998-2011,
https://doi.org/10.2174/0929867323666151221150214 . .

TY  - CONF
AU  - Jovanović, Marija
AU  - Sokić, Dragoslav
AU  - Grabnar, Iztok
AU  - Vovk, Tomaz
AU  - Prostran, Milica
AU  - Erić, Slavica
AU  - Kuzmanovski, Igor
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
PY  - 2015
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2453
PB  - Wiley-Blackwell, Hoboken
C3  - Pharmacotherapy
T1  - Prediction of topiramate serum levels according to variability factors using artificial neural networks.
VL  - 35
IS  - 5
SP  - e75
EP  - e76
DO  - 10.1002/phar.1606
ER  - 

@conference{
author = "Jovanović, Marija and Sokić, Dragoslav and Grabnar, Iztok and Vovk, Tomaz and Prostran, Milica and Erić, Slavica and Kuzmanovski, Igor and Vučićević, Katarina and Miljković, Branislava",
year = "2015",
publisher = "Wiley-Blackwell, Hoboken",
journal = "Pharmacotherapy",
title = "Prediction of topiramate serum levels according to variability factors using artificial neural networks.",
volume = "35",
number = "5",
pages = "e75-e76",
doi = "10.1002/phar.1606"
}

Jovanović, M., Sokić, D., Grabnar, I., Vovk, T., Prostran, M., Erić, S., Kuzmanovski, I., Vučićević, K.,& Miljković, B.. (2015). Prediction of topiramate serum levels according to variability factors using artificial neural networks.. in Pharmacotherapy
Wiley-Blackwell, Hoboken., 35(5), e75-e76.
https://doi.org/10.1002/phar.1606

Jovanović M, Sokić D, Grabnar I, Vovk T, Prostran M, Erić S, Kuzmanovski I, Vučićević K, Miljković B. Prediction of topiramate serum levels according to variability factors using artificial neural networks.. in Pharmacotherapy. 2015;35(5):e75-e76.
doi:10.1002/phar.1606 .

Jovanović, Marija, Sokić, Dragoslav, Grabnar, Iztok, Vovk, Tomaz, Prostran, Milica, Erić, Slavica, Kuzmanovski, Igor, Vučićević, Katarina, Miljković, Branislava, "Prediction of topiramate serum levels according to variability factors using artificial neural networks." in Pharmacotherapy, 35, no. 5 (2015):e75-e76,
https://doi.org/10.1002/phar.1606 . .

TY  - JOUR
AU  - Jovanović, Marija
AU  - Sokić, Dragoslav
AU  - Grabnar, Iztok
AU  - Vovk, Tomaz
AU  - Prostran, Milica
AU  - Erić, Slavica
AU  - Kuzmanovski, Igor
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
PY  - 2015
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2366
AB  - Purpose: The application of artificial neural networks in the pharmaceutical sciences is broad, ranging from drug discovery to clinical pharmacy. In this study, we explored the applicability of counter-propagation artificial neural networks (CPANNs), combined with genetic algorithm (GA) for prediction of topiramate (TPM) serum levels based on identified factors important for its prediction. Methods: The study was performed on 118 TPM measurements obtained from 78 adult epileptic patients. Patients were on stable TPM dosing regimen for at least 7 days; therefore, steady-state was assumed. TPM serum concentration was determined by high performance liquid chromatography with fluorescence detection. The influence of demographic, biochemical parameters and therapy characteristics of the patients on TPM levels were tested. Data analysis was performed by CPANNs. GA was used for optimal CPANN parameters, variable selection and adjustment of relative importance. Results: Data for training included 88 measured TPM concentrations, while remaining were used for validation. Among all factors tested, TPM dose, renal function (eGFR) and carbamazepine dose significantly influenced TPM level and their relative importance were 0.7500, 0.2813, 0.0625, respectively. Relative error and root mean squared relative error (%) and their corresponding 95% confidence intervals for training set were 2.14 [(-2.41) - 6.70] and 21.5 [18.5 - 24.1]; and for test set were 6.21 [(-21.2) - 8.77] and 39.9 [31.7 - 46.7], respectively. Conclusions: Statistical parameters showed acceptable predictive performance. Results indicate the feasibility of CPANNs combined with GA to predict TPM concentrations and to adjust relative importance of identified variability factors in population of adult epileptic patients.
PB  - Canadian Soc Pharmaceutical Sciences, Edmonton
T2  - Journal of Pharmacy and Pharmaceutical Sciences
T1  - Application of Counter-propagation Artificial Neural Networks in Prediction of Topiramate Concentration in Patients with Epilepsy
VL  - 18
IS  - 5
SP  - 856
EP  - 862
DO  - 10.18433/J33031
ER  - 

@article{
author = "Jovanović, Marija and Sokić, Dragoslav and Grabnar, Iztok and Vovk, Tomaz and Prostran, Milica and Erić, Slavica and Kuzmanovski, Igor and Vučićević, Katarina and Miljković, Branislava",
year = "2015",
abstract = "Purpose: The application of artificial neural networks in the pharmaceutical sciences is broad, ranging from drug discovery to clinical pharmacy. In this study, we explored the applicability of counter-propagation artificial neural networks (CPANNs), combined with genetic algorithm (GA) for prediction of topiramate (TPM) serum levels based on identified factors important for its prediction. Methods: The study was performed on 118 TPM measurements obtained from 78 adult epileptic patients. Patients were on stable TPM dosing regimen for at least 7 days; therefore, steady-state was assumed. TPM serum concentration was determined by high performance liquid chromatography with fluorescence detection. The influence of demographic, biochemical parameters and therapy characteristics of the patients on TPM levels were tested. Data analysis was performed by CPANNs. GA was used for optimal CPANN parameters, variable selection and adjustment of relative importance. Results: Data for training included 88 measured TPM concentrations, while remaining were used for validation. Among all factors tested, TPM dose, renal function (eGFR) and carbamazepine dose significantly influenced TPM level and their relative importance were 0.7500, 0.2813, 0.0625, respectively. Relative error and root mean squared relative error (%) and their corresponding 95% confidence intervals for training set were 2.14 [(-2.41) - 6.70] and 21.5 [18.5 - 24.1]; and for test set were 6.21 [(-21.2) - 8.77] and 39.9 [31.7 - 46.7], respectively. Conclusions: Statistical parameters showed acceptable predictive performance. Results indicate the feasibility of CPANNs combined with GA to predict TPM concentrations and to adjust relative importance of identified variability factors in population of adult epileptic patients.",
publisher = "Canadian Soc Pharmaceutical Sciences, Edmonton",
journal = "Journal of Pharmacy and Pharmaceutical Sciences",
title = "Application of Counter-propagation Artificial Neural Networks in Prediction of Topiramate Concentration in Patients with Epilepsy",
volume = "18",
number = "5",
pages = "856-862",
doi = "10.18433/J33031"
}

Jovanović, M., Sokić, D., Grabnar, I., Vovk, T., Prostran, M., Erić, S., Kuzmanovski, I., Vučićević, K.,& Miljković, B.. (2015). Application of Counter-propagation Artificial Neural Networks in Prediction of Topiramate Concentration in Patients with Epilepsy. in Journal of Pharmacy and Pharmaceutical Sciences
Canadian Soc Pharmaceutical Sciences, Edmonton., 18(5), 856-862.
https://doi.org/10.18433/J33031

Jovanović M, Sokić D, Grabnar I, Vovk T, Prostran M, Erić S, Kuzmanovski I, Vučićević K, Miljković B. Application of Counter-propagation Artificial Neural Networks in Prediction of Topiramate Concentration in Patients with Epilepsy. in Journal of Pharmacy and Pharmaceutical Sciences. 2015;18(5):856-862.
doi:10.18433/J33031 .

Jovanović, Marija, Sokić, Dragoslav, Grabnar, Iztok, Vovk, Tomaz, Prostran, Milica, Erić, Slavica, Kuzmanovski, Igor, Vučićević, Katarina, Miljković, Branislava, "Application of Counter-propagation Artificial Neural Networks in Prediction of Topiramate Concentration in Patients with Epilepsy" in Journal of Pharmacy and Pharmaceutical Sciences, 18, no. 5 (2015):856-862,
https://doi.org/10.18433/J33031 . .

TY  - CONF
AU  - Jovanović, Marija
AU  - Sokić, Dragoslav
AU  - Grabnar, Iztok
AU  - Prostran, Milica
AU  - Obrenović, Radmila
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
PY  - 2014
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2198
PB  - Wiley-Blackwell, Hoboken
C3  - Pharmacotherapy
T1  - Influence of topiramate therapy duration on serum bicarbonate levels in adults
VL  - 34
IS  - 6
SP  - e110
EP  - e110
DO  - 10.1002/phar.1449
ER  - 

@conference{
author = "Jovanović, Marija and Sokić, Dragoslav and Grabnar, Iztok and Prostran, Milica and Obrenović, Radmila and Vučićević, Katarina and Miljković, Branislava",
year = "2014",
publisher = "Wiley-Blackwell, Hoboken",
journal = "Pharmacotherapy",
title = "Influence of topiramate therapy duration on serum bicarbonate levels in adults",
volume = "34",
number = "6",
pages = "e110-e110",
doi = "10.1002/phar.1449"
}

Jovanović, M., Sokić, D., Grabnar, I., Prostran, M., Obrenović, R., Vučićević, K.,& Miljković, B.. (2014). Influence of topiramate therapy duration on serum bicarbonate levels in adults. in Pharmacotherapy
Wiley-Blackwell, Hoboken., 34(6), e110-e110.
https://doi.org/10.1002/phar.1449

Jovanović M, Sokić D, Grabnar I, Prostran M, Obrenović R, Vučićević K, Miljković B. Influence of topiramate therapy duration on serum bicarbonate levels in adults. in Pharmacotherapy. 2014;34(6):e110-e110.
doi:10.1002/phar.1449 .

Jovanović, Marija, Sokić, Dragoslav, Grabnar, Iztok, Prostran, Milica, Obrenović, Radmila, Vučićević, Katarina, Miljković, Branislava, "Influence of topiramate therapy duration on serum bicarbonate levels in adults" in Pharmacotherapy, 34, no. 6 (2014):e110-e110,
https://doi.org/10.1002/phar.1449 . .

TY  - JOUR
AU  - Jovanović, Marija
AU  - Sokić, Dragoslav
AU  - Grabnar, Iztok
AU  - Prostran, Milica
AU  - Obrenović, Radmila
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
PY  - 2014
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2091
AB  - Background: Topiramate (TPM) is a sulfamate-substituted monosaccharide that is structurally different from other antiepileptic drugs. TPM inhibits carbonic anhydrase activity, which is associated with loss of bicarbonate from the kidney and consequently metabolic acidosis or electrolyte imbalance. Objective: The objectives of the study were to investigate the influence of TPM therapy on bicarbonate and potassium levels in adult epileptic patients. Methods: Data were collected from 59 adult patients on monotherapy or co-therapy of TPM and other antiepileptic drugs. Serum bicarbonate and potassium levels were available from all patients. Steady-state TPM trough concentrations were determined in blood samples by high-performance liquid chromatography. Data analysis was performed by SPSS software (version 17, Chicago, IL). Results: Patients were divided into group A (duration of therapy shorter than or equal to 5 years) and group B (duration of therapy longer than 5 years). Significant difference (P  lt  0.05) in serum bicarbonate levels was observed between these 2 groups. Bicarbonate levels were linearly related to the TPM therapy duration. No correlation was found between the TPM dose or patient age and bicarbonate or potassium levels, as well as between therapy duration and potassium level. Linear regression analysis showed no significant association among 54 available TPM trough concentrations and bicarbonate or potassium levels. Conclusions: Results highlight the frequent occurrence of lower bicarbonate level associated with prolonged TPM therapy. Monitoring bicarbonate levels in patients on long-term TPM therapy might be useful.
PB  - Sage Publications Inc, Thousand Oaks
T2  - Annals of Pharmacotherapy
T1  - Effect of Long-term Topiramate Therapy on Serum Bicarbonate and Potassium Levels in Adult Epileptic Patients
VL  - 48
IS  - 8
SP  - 992
EP  - 997
DO  - 10.1177/1060028014534397
ER  - 

@article{
author = "Jovanović, Marija and Sokić, Dragoslav and Grabnar, Iztok and Prostran, Milica and Obrenović, Radmila and Vučićević, Katarina and Miljković, Branislava",
year = "2014",
abstract = "Background: Topiramate (TPM) is a sulfamate-substituted monosaccharide that is structurally different from other antiepileptic drugs. TPM inhibits carbonic anhydrase activity, which is associated with loss of bicarbonate from the kidney and consequently metabolic acidosis or electrolyte imbalance. Objective: The objectives of the study were to investigate the influence of TPM therapy on bicarbonate and potassium levels in adult epileptic patients. Methods: Data were collected from 59 adult patients on monotherapy or co-therapy of TPM and other antiepileptic drugs. Serum bicarbonate and potassium levels were available from all patients. Steady-state TPM trough concentrations were determined in blood samples by high-performance liquid chromatography. Data analysis was performed by SPSS software (version 17, Chicago, IL). Results: Patients were divided into group A (duration of therapy shorter than or equal to 5 years) and group B (duration of therapy longer than 5 years). Significant difference (P  lt  0.05) in serum bicarbonate levels was observed between these 2 groups. Bicarbonate levels were linearly related to the TPM therapy duration. No correlation was found between the TPM dose or patient age and bicarbonate or potassium levels, as well as between therapy duration and potassium level. Linear regression analysis showed no significant association among 54 available TPM trough concentrations and bicarbonate or potassium levels. Conclusions: Results highlight the frequent occurrence of lower bicarbonate level associated with prolonged TPM therapy. Monitoring bicarbonate levels in patients on long-term TPM therapy might be useful.",
publisher = "Sage Publications Inc, Thousand Oaks",
journal = "Annals of Pharmacotherapy",
title = "Effect of Long-term Topiramate Therapy on Serum Bicarbonate and Potassium Levels in Adult Epileptic Patients",
volume = "48",
number = "8",
pages = "992-997",
doi = "10.1177/1060028014534397"
}

Jovanović, M., Sokić, D., Grabnar, I., Prostran, M., Obrenović, R., Vučićević, K.,& Miljković, B.. (2014). Effect of Long-term Topiramate Therapy on Serum Bicarbonate and Potassium Levels in Adult Epileptic Patients. in Annals of Pharmacotherapy
Sage Publications Inc, Thousand Oaks., 48(8), 992-997.
https://doi.org/10.1177/1060028014534397

Jovanović M, Sokić D, Grabnar I, Prostran M, Obrenović R, Vučićević K, Miljković B. Effect of Long-term Topiramate Therapy on Serum Bicarbonate and Potassium Levels in Adult Epileptic Patients. in Annals of Pharmacotherapy. 2014;48(8):992-997.
doi:10.1177/1060028014534397 .

Jovanović, Marija, Sokić, Dragoslav, Grabnar, Iztok, Prostran, Milica, Obrenović, Radmila, Vučićević, Katarina, Miljković, Branislava, "Effect of Long-term Topiramate Therapy on Serum Bicarbonate and Potassium Levels in Adult Epileptic Patients" in Annals of Pharmacotherapy, 48, no. 8 (2014):992-997,
https://doi.org/10.1177/1060028014534397 . .

TY  - JOUR
AU  - Jovanović, Marija
AU  - Sokić, Dragoslav
AU  - Grabnar, Iztok
AU  - Vovk, Tomaz
AU  - Prostran, Milica
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
PY  - 2013
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1844
AB  - The objective of the study was to develop population pharmacokinetic model of topiramate (TPM) using nonlinear mixed effects modelling approach. Data were collected from 78 adult epileptic patients on mono- or co-therapy of TPM and other antiepileptic drugs, such as carbamazepine (CBZ), valproic acid, lamotrigine, levetiracetam, phenobarbital and pregabalin. Steady-state TPM concentrations were determined in blood samples by high performance liquid chromatography with fluorescence detection. A one-compartment model with first order absorption and elimination was used to fit the concentration-time TPM data. Volume of distribution of TPM was estimated at 0.575 l/kg. The influence of demographic, biochemical parameters and therapy characteristics of the patients on oral clearance (CL/F) was evaluated. Daily carbamazepine dose (DCBZ) and renal function estimated by Modification of diet in renal disease (MDRD) formula significantly (p  lt  0.001) influenced CL/F and were included in the final model: CL/F . (l/h) = 1.53(1/h) . [1 + 0.476 . DCBZ(mg/day)/1000(mg/day)] . EXP[0.00476 . [MDRD(ml/min) -95.72(ml/ mm)]]. Increase of CL/F with DCBZ and MDRD was best described by linear and exponential models. Mean TPM CL/F during CBZ co-therapy was 2.46 l/h, which is higher for 60.8% than in patients not co-treated with CBZ. Evaluation by bootstrapping showed that the final model was stable. The predictive performance was evaluated by adequate plots and indicated satisfactory precision. This model allows individualisation of TPM dosing in routine patient care, especially useful for patients on different CBZ dosing regimen.
PB  - Elsevier Science BV, Amsterdam
T2  - European Journal of Pharmaceutical Sciences
T1  - Population pharmacokinetics of topiramate in adult patients with epilepsy using nonlinear mixed effects modelling
VL  - 50
IS  - 3-4
SP  - 282
EP  - 289
DO  - 10.1016/j.ejps.2013.07.008
ER  - 

@article{
author = "Jovanović, Marija and Sokić, Dragoslav and Grabnar, Iztok and Vovk, Tomaz and Prostran, Milica and Vučićević, Katarina and Miljković, Branislava",
year = "2013",
abstract = "The objective of the study was to develop population pharmacokinetic model of topiramate (TPM) using nonlinear mixed effects modelling approach. Data were collected from 78 adult epileptic patients on mono- or co-therapy of TPM and other antiepileptic drugs, such as carbamazepine (CBZ), valproic acid, lamotrigine, levetiracetam, phenobarbital and pregabalin. Steady-state TPM concentrations were determined in blood samples by high performance liquid chromatography with fluorescence detection. A one-compartment model with first order absorption and elimination was used to fit the concentration-time TPM data. Volume of distribution of TPM was estimated at 0.575 l/kg. The influence of demographic, biochemical parameters and therapy characteristics of the patients on oral clearance (CL/F) was evaluated. Daily carbamazepine dose (DCBZ) and renal function estimated by Modification of diet in renal disease (MDRD) formula significantly (p  lt  0.001) influenced CL/F and were included in the final model: CL/F . (l/h) = 1.53(1/h) . [1 + 0.476 . DCBZ(mg/day)/1000(mg/day)] . EXP[0.00476 . [MDRD(ml/min) -95.72(ml/ mm)]]. Increase of CL/F with DCBZ and MDRD was best described by linear and exponential models. Mean TPM CL/F during CBZ co-therapy was 2.46 l/h, which is higher for 60.8% than in patients not co-treated with CBZ. Evaluation by bootstrapping showed that the final model was stable. The predictive performance was evaluated by adequate plots and indicated satisfactory precision. This model allows individualisation of TPM dosing in routine patient care, especially useful for patients on different CBZ dosing regimen.",
publisher = "Elsevier Science BV, Amsterdam",
journal = "European Journal of Pharmaceutical Sciences",
title = "Population pharmacokinetics of topiramate in adult patients with epilepsy using nonlinear mixed effects modelling",
volume = "50",
number = "3-4",
pages = "282-289",
doi = "10.1016/j.ejps.2013.07.008"
}

Jovanović, M., Sokić, D., Grabnar, I., Vovk, T., Prostran, M., Vučićević, K.,& Miljković, B.. (2013). Population pharmacokinetics of topiramate in adult patients with epilepsy using nonlinear mixed effects modelling. in European Journal of Pharmaceutical Sciences
Elsevier Science BV, Amsterdam., 50(3-4), 282-289.
https://doi.org/10.1016/j.ejps.2013.07.008

Jovanović M, Sokić D, Grabnar I, Vovk T, Prostran M, Vučićević K, Miljković B. Population pharmacokinetics of topiramate in adult patients with epilepsy using nonlinear mixed effects modelling. in European Journal of Pharmaceutical Sciences. 2013;50(3-4):282-289.
doi:10.1016/j.ejps.2013.07.008 .

Jovanović, Marija, Sokić, Dragoslav, Grabnar, Iztok, Vovk, Tomaz, Prostran, Milica, Vučićević, Katarina, Miljković, Branislava, "Population pharmacokinetics of topiramate in adult patients with epilepsy using nonlinear mixed effects modelling" in European Journal of Pharmaceutical Sciences, 50, no. 3-4 (2013):282-289,
https://doi.org/10.1016/j.ejps.2013.07.008 . .

TY  - CONF
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
AU  - Pokrajac, Milena
AU  - Prostran, Milica
AU  - Martinović, Žarko J.
AU  - Veličković, Ružica
AU  - Grabnar, Iztok
PY  - 2010
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1348
PB  - Elsevier Science BV, Amsterdam
C3  - European Neuropsychopharmacology
T1  - Assessment of benzodiazepines-valproic acid pharmacokinetic interaction in adult epileptic patients: population approach
VL  - 20
IS  - Supplement 3
SP  - S247
EP  - S248
DO  - 10.1016/S0924-977X(10)70310-2
ER  - 

@conference{
author = "Vučićević, Katarina and Miljković, Branislava and Pokrajac, Milena and Prostran, Milica and Martinović, Žarko J. and Veličković, Ružica and Grabnar, Iztok",
year = "2010",
publisher = "Elsevier Science BV, Amsterdam",
journal = "European Neuropsychopharmacology",
title = "Assessment of benzodiazepines-valproic acid pharmacokinetic interaction in adult epileptic patients: population approach",
volume = "20",
number = "Supplement 3",
pages = "S247-S248",
doi = "10.1016/S0924-977X(10)70310-2"
}

Vučićević, K., Miljković, B., Pokrajac, M., Prostran, M., Martinović, Ž. J., Veličković, R.,& Grabnar, I.. (2010). Assessment of benzodiazepines-valproic acid pharmacokinetic interaction in adult epileptic patients: population approach. in European Neuropsychopharmacology
Elsevier Science BV, Amsterdam., 20(Supplement 3), S247-S248.
https://doi.org/10.1016/S0924-977X(10)70310-2

Vučićević K, Miljković B, Pokrajac M, Prostran M, Martinović ŽJ, Veličković R, Grabnar I. Assessment of benzodiazepines-valproic acid pharmacokinetic interaction in adult epileptic patients: population approach. in European Neuropsychopharmacology. 2010;20(Supplement 3):S247-S248.
doi:10.1016/S0924-977X(10)70310-2 .

Vučićević, Katarina, Miljković, Branislava, Pokrajac, Milena, Prostran, Milica, Martinović, Žarko J., Veličković, Ružica, Grabnar, Iztok, "Assessment of benzodiazepines-valproic acid pharmacokinetic interaction in adult epileptic patients: population approach" in European Neuropsychopharmacology, 20, no. Supplement 3 (2010):S247-S248,
https://doi.org/10.1016/S0924-977X(10)70310-2 . .

TY  - CONF
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
AU  - Pokrajac, Milena
AU  - Grabnar, Iztok
PY  - 2009
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1171
PB  - Elsevier Science BV, Amsterdam
C3  - European Neuropsychopharmacology
T1  - Effect of topiramate on valproic acid clearance in adult patients with epilepsy: a population pharmacokinetic study
VL  - 19
IS  - Supplement 3
SP  - S271
EP  - S271
DO  - 10.1016/S0924-977X(09)70394-3
ER  - 

@conference{
author = "Vučićević, Katarina and Miljković, Branislava and Pokrajac, Milena and Grabnar, Iztok",
year = "2009",
publisher = "Elsevier Science BV, Amsterdam",
journal = "European Neuropsychopharmacology",
title = "Effect of topiramate on valproic acid clearance in adult patients with epilepsy: a population pharmacokinetic study",
volume = "19",
number = "Supplement 3",
pages = "S271-S271",
doi = "10.1016/S0924-977X(09)70394-3"
}

Vučićević, K., Miljković, B., Pokrajac, M.,& Grabnar, I.. (2009). Effect of topiramate on valproic acid clearance in adult patients with epilepsy: a population pharmacokinetic study. in European Neuropsychopharmacology
Elsevier Science BV, Amsterdam., 19(Supplement 3), S271-S271.
https://doi.org/10.1016/S0924-977X(09)70394-3

Vučićević K, Miljković B, Pokrajac M, Grabnar I. Effect of topiramate on valproic acid clearance in adult patients with epilepsy: a population pharmacokinetic study. in European Neuropsychopharmacology. 2009;19(Supplement 3):S271-S271.
doi:10.1016/S0924-977X(09)70394-3 .

Vučićević, Katarina, Miljković, Branislava, Pokrajac, Milena, Grabnar, Iztok, "Effect of topiramate on valproic acid clearance in adult patients with epilepsy: a population pharmacokinetic study" in European Neuropsychopharmacology, 19, no. Supplement 3 (2009):S271-S271,
https://doi.org/10.1016/S0924-977X(09)70394-3 . .

TY  - CONF
AU  - Vovk, Tomaz
AU  - Grabnar, Iztok
AU  - Kos, M. Kerec
AU  - Jakovljević, M. B.
AU  - Vučićević, Katarina
AU  - Mrhar, Ales
PY  - 2009
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1265
PB  - Elsevier Science BV, Amsterdam
C3  - European Journal of Pharmaceutical Sciences
T1  - The role of therapeutic drug monitoring in optimazing pharmacotherapy of selected antiepileptics
VL  - 38
IS  - 1
SP  - 51
EP  - 52
UR  - https://hdl.handle.net/21.15107/rcub_farfar_1265
ER  - 

@conference{
author = "Vovk, Tomaz and Grabnar, Iztok and Kos, M. Kerec and Jakovljević, M. B. and Vučićević, Katarina and Mrhar, Ales",
year = "2009",
publisher = "Elsevier Science BV, Amsterdam",
journal = "European Journal of Pharmaceutical Sciences",
title = "The role of therapeutic drug monitoring in optimazing pharmacotherapy of selected antiepileptics",
volume = "38",
number = "1",
pages = "51-52",
url = "https://hdl.handle.net/21.15107/rcub_farfar_1265"
}

Vovk, T., Grabnar, I., Kos, M. K., Jakovljević, M. B., Vučićević, K.,& Mrhar, A.. (2009). The role of therapeutic drug monitoring in optimazing pharmacotherapy of selected antiepileptics. in European Journal of Pharmaceutical Sciences
Elsevier Science BV, Amsterdam., 38(1), 51-52.
https://hdl.handle.net/21.15107/rcub_farfar_1265

Vovk T, Grabnar I, Kos MK, Jakovljević MB, Vučićević K, Mrhar A. The role of therapeutic drug monitoring in optimazing pharmacotherapy of selected antiepileptics. in European Journal of Pharmaceutical Sciences. 2009;38(1):51-52.
https://hdl.handle.net/21.15107/rcub_farfar_1265 .

Vovk, Tomaz, Grabnar, Iztok, Kos, M. Kerec, Jakovljević, M. B., Vučićević, Katarina, Mrhar, Ales, "The role of therapeutic drug monitoring in optimazing pharmacotherapy of selected antiepileptics" in European Journal of Pharmaceutical Sciences, 38, no. 1 (2009):51-52,
https://hdl.handle.net/21.15107/rcub_farfar_1265 .

TY  - CONF
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
AU  - Petronijević, Marija
AU  - Pokrajac, Milena
AU  - Veličković, Ružica
AU  - Mrhar, Ales
AU  - Grabnar, Iztok
PY  - 2009
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1240
PB  - Springer, Dordrecht
C3  - Pharmacy World & Science
T1  - No effect of gender on carbamazepine elimination-population approach
VL  - 31
IS  - 1
SP  - 118
EP  - 119
UR  - https://hdl.handle.net/21.15107/rcub_farfar_1240
ER  - 

@conference{
author = "Vučićević, Katarina and Miljković, Branislava and Petronijević, Marija and Pokrajac, Milena and Veličković, Ružica and Mrhar, Ales and Grabnar, Iztok",
year = "2009",
publisher = "Springer, Dordrecht",
journal = "Pharmacy World & Science",
title = "No effect of gender on carbamazepine elimination-population approach",
volume = "31",
number = "1",
pages = "118-119",
url = "https://hdl.handle.net/21.15107/rcub_farfar_1240"
}

Vučićević, K., Miljković, B., Petronijević, M., Pokrajac, M., Veličković, R., Mrhar, A.,& Grabnar, I.. (2009). No effect of gender on carbamazepine elimination-population approach. in Pharmacy World & Science
Springer, Dordrecht., 31(1), 118-119.
https://hdl.handle.net/21.15107/rcub_farfar_1240

Vučićević K, Miljković B, Petronijević M, Pokrajac M, Veličković R, Mrhar A, Grabnar I. No effect of gender on carbamazepine elimination-population approach. in Pharmacy World & Science. 2009;31(1):118-119.
https://hdl.handle.net/21.15107/rcub_farfar_1240 .

Vučićević, Katarina, Miljković, Branislava, Petronijević, Marija, Pokrajac, Milena, Veličković, Ružica, Mrhar, Ales, Grabnar, Iztok, "No effect of gender on carbamazepine elimination-population approach" in Pharmacy World & Science, 31, no. 1 (2009):118-119,
https://hdl.handle.net/21.15107/rcub_farfar_1240 .

TY  - CONF
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
AU  - Pokrajac, Milena
AU  - Grabnar, Iztok
PY  - 2009
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1219
PB  - Springer, Dordrecht
C3  - Pharmacy World & Science
T1  - Effect of patient weight and carbamazepine daily dose on carbamazepine clearance-a population pharmacokinetic study
VL  - 31
IS  - 2
SP  - 332
EP  - 333
UR  - https://hdl.handle.net/21.15107/rcub_farfar_1219
ER  - 

@conference{
author = "Vučićević, Katarina and Miljković, Branislava and Pokrajac, Milena and Grabnar, Iztok",
year = "2009",
publisher = "Springer, Dordrecht",
journal = "Pharmacy World & Science",
title = "Effect of patient weight and carbamazepine daily dose on carbamazepine clearance-a population pharmacokinetic study",
volume = "31",
number = "2",
pages = "332-333",
url = "https://hdl.handle.net/21.15107/rcub_farfar_1219"
}

Vučićević, K., Miljković, B., Pokrajac, M.,& Grabnar, I.. (2009). Effect of patient weight and carbamazepine daily dose on carbamazepine clearance-a population pharmacokinetic study. in Pharmacy World & Science
Springer, Dordrecht., 31(2), 332-333.
https://hdl.handle.net/21.15107/rcub_farfar_1219

Vučićević K, Miljković B, Pokrajac M, Grabnar I. Effect of patient weight and carbamazepine daily dose on carbamazepine clearance-a population pharmacokinetic study. in Pharmacy World & Science. 2009;31(2):332-333.
https://hdl.handle.net/21.15107/rcub_farfar_1219 .

Vučićević, Katarina, Miljković, Branislava, Pokrajac, Milena, Grabnar, Iztok, "Effect of patient weight and carbamazepine daily dose on carbamazepine clearance-a population pharmacokinetic study" in Pharmacy World & Science, 31, no. 2 (2009):332-333,
https://hdl.handle.net/21.15107/rcub_farfar_1219 .

TY  - JOUR
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
AU  - Pokrajac, Milena
AU  - Prostran, Milica
AU  - Martinović, Žarko J.
AU  - Grabnar, Iztok
PY  - 2009
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1211
AB  - Monitoring valproic acid (VPA) concentrations is especially challenging due to its highly variable pharmacokinetics (PK) and complex interactions with other antiepileptic drugs. We used sparse routine therapeutic drug monitoring data (n = 200) from 129 adults with epilepsy to develop a population PK model of VPA, and determine the factors that influence its clearance (CL/F). Patients were on mono VPA therapy, or were concomitantly treated with carbamazepine, phenobarbital, topiramate (TPR), lamotrigine or benzodiazepines. A one-compartment model with first-order absorption and elimination was used to fit the concentration-time VPA data. Estimates generated by NONMEM indicated that VPA CL/F was influenced by the patients' body weight (increases with the 0.556 exponent), VPA daily dose (if it is greater than 1000 mg/day, CL/F increases by 43%), and co-therapy with TPR (lowering CL/F for 23%). The interindividual variability in VPA CL/F was modeled with exponentional error model. The estimated coefficient of variation was 31.9%, while the residual variability was 23.8% for the proportional and 13.2 mg/l for the additive component. The model was validated in a separate set of 24 patients, and the predictive performance was evaluated, that indicated unbias and acceptable precision. This study confirms the interaction of VPA with TPR, which is presumably dependent on VPA dose.
PB  - Elsevier Science BV, Amsterdam
T2  - European Journal of Pharmaceutical Sciences
T1  - The influence of drug-drug interaction and patients' characteristics on valproic acid's clearance in adults with epilepsy using nonlinear mixed effects modeling
VL  - 38
IS  - 5
SP  - 512
EP  - 518
DO  - 10.1016/j.ejps.2009.09.017
ER  - 

@article{
author = "Vučićević, Katarina and Miljković, Branislava and Pokrajac, Milena and Prostran, Milica and Martinović, Žarko J. and Grabnar, Iztok",
year = "2009",
abstract = "Monitoring valproic acid (VPA) concentrations is especially challenging due to its highly variable pharmacokinetics (PK) and complex interactions with other antiepileptic drugs. We used sparse routine therapeutic drug monitoring data (n = 200) from 129 adults with epilepsy to develop a population PK model of VPA, and determine the factors that influence its clearance (CL/F). Patients were on mono VPA therapy, or were concomitantly treated with carbamazepine, phenobarbital, topiramate (TPR), lamotrigine or benzodiazepines. A one-compartment model with first-order absorption and elimination was used to fit the concentration-time VPA data. Estimates generated by NONMEM indicated that VPA CL/F was influenced by the patients' body weight (increases with the 0.556 exponent), VPA daily dose (if it is greater than 1000 mg/day, CL/F increases by 43%), and co-therapy with TPR (lowering CL/F for 23%). The interindividual variability in VPA CL/F was modeled with exponentional error model. The estimated coefficient of variation was 31.9%, while the residual variability was 23.8% for the proportional and 13.2 mg/l for the additive component. The model was validated in a separate set of 24 patients, and the predictive performance was evaluated, that indicated unbias and acceptable precision. This study confirms the interaction of VPA with TPR, which is presumably dependent on VPA dose.",
publisher = "Elsevier Science BV, Amsterdam",
journal = "European Journal of Pharmaceutical Sciences",
title = "The influence of drug-drug interaction and patients' characteristics on valproic acid's clearance in adults with epilepsy using nonlinear mixed effects modeling",
volume = "38",
number = "5",
pages = "512-518",
doi = "10.1016/j.ejps.2009.09.017"
}

Vučićević, K., Miljković, B., Pokrajac, M., Prostran, M., Martinović, Ž. J.,& Grabnar, I.. (2009). The influence of drug-drug interaction and patients' characteristics on valproic acid's clearance in adults with epilepsy using nonlinear mixed effects modeling. in European Journal of Pharmaceutical Sciences
Elsevier Science BV, Amsterdam., 38(5), 512-518.
https://doi.org/10.1016/j.ejps.2009.09.017

Vučićević K, Miljković B, Pokrajac M, Prostran M, Martinović ŽJ, Grabnar I. The influence of drug-drug interaction and patients' characteristics on valproic acid's clearance in adults with epilepsy using nonlinear mixed effects modeling. in European Journal of Pharmaceutical Sciences. 2009;38(5):512-518.
doi:10.1016/j.ejps.2009.09.017 .

Vučićević, Katarina, Miljković, Branislava, Pokrajac, Milena, Prostran, Milica, Martinović, Žarko J., Grabnar, Iztok, "The influence of drug-drug interaction and patients' characteristics on valproic acid's clearance in adults with epilepsy using nonlinear mixed effects modeling" in European Journal of Pharmaceutical Sciences, 38, no. 5 (2009):512-518,
https://doi.org/10.1016/j.ejps.2009.09.017 . .

TY  - CONF
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
AU  - Petronijević, Marija
AU  - Pokrajac, Milena
AU  - Mrhar, Ales
AU  - Grabnar, Iztok
PY  - 2008
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1109
PB  - Springer, Dordrecht
C3  - Pharmacy World & Science
T1  - Effect of co-treatment with valproic acid on carbamazepine elimination in epileptic patients a population pharmacokinetic study
VL  - 30
IS  - 5
SP  - 673
EP  - 674
UR  - https://hdl.handle.net/21.15107/rcub_farfar_1109
ER  - 

@conference{
author = "Vučićević, Katarina and Miljković, Branislava and Petronijević, Marija and Pokrajac, Milena and Mrhar, Ales and Grabnar, Iztok",
year = "2008",
publisher = "Springer, Dordrecht",
journal = "Pharmacy World & Science",
title = "Effect of co-treatment with valproic acid on carbamazepine elimination in epileptic patients a population pharmacokinetic study",
volume = "30",
number = "5",
pages = "673-674",
url = "https://hdl.handle.net/21.15107/rcub_farfar_1109"
}

Vučićević, K., Miljković, B., Petronijević, M., Pokrajac, M., Mrhar, A.,& Grabnar, I.. (2008). Effect of co-treatment with valproic acid on carbamazepine elimination in epileptic patients a population pharmacokinetic study. in Pharmacy World & Science
Springer, Dordrecht., 30(5), 673-674.
https://hdl.handle.net/21.15107/rcub_farfar_1109

Vučićević K, Miljković B, Petronijević M, Pokrajac M, Mrhar A, Grabnar I. Effect of co-treatment with valproic acid on carbamazepine elimination in epileptic patients a population pharmacokinetic study. in Pharmacy World & Science. 2008;30(5):673-674.
https://hdl.handle.net/21.15107/rcub_farfar_1109 .

Vučićević, Katarina, Miljković, Branislava, Petronijević, Marija, Pokrajac, Milena, Mrhar, Ales, Grabnar, Iztok, "Effect of co-treatment with valproic acid on carbamazepine elimination in epileptic patients a population pharmacokinetic study" in Pharmacy World & Science, 30, no. 5 (2008):673-674,
https://hdl.handle.net/21.15107/rcub_farfar_1109 .

TY  - CONF
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
AU  - Petronijević, M.
AU  - Pokrajac, Milena
AU  - Veličković, Ružica
AU  - Grabnar, Iztok
PY  - 2007
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/896
PB  - Elsevier Science BV, Amsterdam
C3  - European Neuropsychopharmacology
T1  - Induction of carbamazepine metabolism during co-treatment with phenobarbitone - a population pharmacokinetic study
VL  - 17
IS  - Supplement 4
SP  - S261
EP  - S262
DO  - 10.1016/S0924-977X(07)70358-9
ER  - 

@conference{
author = "Vučićević, Katarina and Miljković, Branislava and Petronijević, M. and Pokrajac, Milena and Veličković, Ružica and Grabnar, Iztok",
year = "2007",
publisher = "Elsevier Science BV, Amsterdam",
journal = "European Neuropsychopharmacology",
title = "Induction of carbamazepine metabolism during co-treatment with phenobarbitone - a population pharmacokinetic study",
volume = "17",
number = "Supplement 4",
pages = "S261-S262",
doi = "10.1016/S0924-977X(07)70358-9"
}

Vučićević, K., Miljković, B., Petronijević, M., Pokrajac, M., Veličković, R.,& Grabnar, I.. (2007). Induction of carbamazepine metabolism during co-treatment with phenobarbitone - a population pharmacokinetic study. in European Neuropsychopharmacology
Elsevier Science BV, Amsterdam., 17(Supplement 4), S261-S262.
https://doi.org/10.1016/S0924-977X(07)70358-9

Vučićević K, Miljković B, Petronijević M, Pokrajac M, Veličković R, Grabnar I. Induction of carbamazepine metabolism during co-treatment with phenobarbitone - a population pharmacokinetic study. in European Neuropsychopharmacology. 2007;17(Supplement 4):S261-S262.
doi:10.1016/S0924-977X(07)70358-9 .

Vučićević, Katarina, Miljković, Branislava, Petronijević, M., Pokrajac, Milena, Veličković, Ružica, Grabnar, Iztok, "Induction of carbamazepine metabolism during co-treatment with phenobarbitone - a population pharmacokinetic study" in European Neuropsychopharmacology, 17, no. Supplement 4 (2007):S261-S262,
https://doi.org/10.1016/S0924-977X(07)70358-9 . .

TY  - JOUR
AU  - Vučićević, Katarina
AU  - Milijković, Branislava
AU  - Veličković, Ružica
AU  - Pokrajac, Milena
AU  - Mrhar, Ales
AU  - Grabnar, Iztok
PY  - 2007
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/898
AB  - The aim of the present study was to develop a population pharmacokinetic model of carbamazepine from routine therapeutic drug monitoring data. Steady-state carbamazepine plasma concentrations determined by homogenous enzyme immunoassay technique, dosing history including cotherapy, schedule of blood sampling, and patients' demographic characteristics were collected retrospectively from patients' chart histories. A one-compartment model was fitted to the data using nonlinear mixed effects modeling. The influence of weight, age, gender, smoking, allergy, carbamazepine daily dose, and cotherapy on clearance (CL/F) was evaluated. Additionally, bioavailability of controlled-release relative to immediate-release tablets was assessed. Two hundred sixty-five patients (423 concentrations) were used to develop a population pharmacokinetic model. The population estimate of CL/F from the base model was 5.14 L/h with interindividual variability of 50.20%. Patients' gender, age, smoking, allergy, cotherapy with lamotrigine and benzodiazepines had no effect on CUE Patient weight (WT), daily carbamazepine dose (DCBZ), daily dose of phenobarbitone (DPB) and valproic acid (VPA), when its daily dose exceeded 750 mg, significantly influenced CL/F and were included in the final model: CL/F [L/h] = 5.35 (DCBZ [mg/da/kg]/15)(0.591) (1 + 0.414 (DPB [mg/day/kg]/2) (WT [kg]/70)(0.564) 1.18(VPA) where VPA is 1 if dose is greater than 750 mg or 0 otherwise. No difference in bioavailability of carbamazepine between controlled and immediate-release tablets was detected. The model predictions in the validation set had no bias and satisfactory precision. The model can be used for estimation of carbamazepine CL/F in individual patients in the postautoinduction phase and for selection of optimum dosing regimen in routine patient care.
PB  - Lippincott Williams & Wilkins, Philadelphia
T2  - Therapeutic Drug Monitoring
T1  - Population pharmacokinetic model of carbamazepine derived from routine therapeutic drug monitoring data
VL  - 29
IS  - 6
SP  - 781
EP  - 788
UR  - https://hdl.handle.net/21.15107/rcub_farfar_898
ER  - 

@article{
author = "Vučićević, Katarina and Milijković, Branislava and Veličković, Ružica and Pokrajac, Milena and Mrhar, Ales and Grabnar, Iztok",
year = "2007",
abstract = "The aim of the present study was to develop a population pharmacokinetic model of carbamazepine from routine therapeutic drug monitoring data. Steady-state carbamazepine plasma concentrations determined by homogenous enzyme immunoassay technique, dosing history including cotherapy, schedule of blood sampling, and patients' demographic characteristics were collected retrospectively from patients' chart histories. A one-compartment model was fitted to the data using nonlinear mixed effects modeling. The influence of weight, age, gender, smoking, allergy, carbamazepine daily dose, and cotherapy on clearance (CL/F) was evaluated. Additionally, bioavailability of controlled-release relative to immediate-release tablets was assessed. Two hundred sixty-five patients (423 concentrations) were used to develop a population pharmacokinetic model. The population estimate of CL/F from the base model was 5.14 L/h with interindividual variability of 50.20%. Patients' gender, age, smoking, allergy, cotherapy with lamotrigine and benzodiazepines had no effect on CUE Patient weight (WT), daily carbamazepine dose (DCBZ), daily dose of phenobarbitone (DPB) and valproic acid (VPA), when its daily dose exceeded 750 mg, significantly influenced CL/F and were included in the final model: CL/F [L/h] = 5.35 (DCBZ [mg/da/kg]/15)(0.591) (1 + 0.414 (DPB [mg/day/kg]/2) (WT [kg]/70)(0.564) 1.18(VPA) where VPA is 1 if dose is greater than 750 mg or 0 otherwise. No difference in bioavailability of carbamazepine between controlled and immediate-release tablets was detected. The model predictions in the validation set had no bias and satisfactory precision. The model can be used for estimation of carbamazepine CL/F in individual patients in the postautoinduction phase and for selection of optimum dosing regimen in routine patient care.",
publisher = "Lippincott Williams & Wilkins, Philadelphia",
journal = "Therapeutic Drug Monitoring",
title = "Population pharmacokinetic model of carbamazepine derived from routine therapeutic drug monitoring data",
volume = "29",
number = "6",
pages = "781-788",
url = "https://hdl.handle.net/21.15107/rcub_farfar_898"
}

Vučićević, K., Milijković, B., Veličković, R., Pokrajac, M., Mrhar, A.,& Grabnar, I.. (2007). Population pharmacokinetic model of carbamazepine derived from routine therapeutic drug monitoring data. in Therapeutic Drug Monitoring
Lippincott Williams & Wilkins, Philadelphia., 29(6), 781-788.
https://hdl.handle.net/21.15107/rcub_farfar_898

Vučićević K, Milijković B, Veličković R, Pokrajac M, Mrhar A, Grabnar I. Population pharmacokinetic model of carbamazepine derived from routine therapeutic drug monitoring data. in Therapeutic Drug Monitoring. 2007;29(6):781-788.
https://hdl.handle.net/21.15107/rcub_farfar_898 .

Vučićević, Katarina, Milijković, Branislava, Veličković, Ružica, Pokrajac, Milena, Mrhar, Ales, Grabnar, Iztok, "Population pharmacokinetic model of carbamazepine derived from routine therapeutic drug monitoring data" in Therapeutic Drug Monitoring, 29, no. 6 (2007):781-788,
https://hdl.handle.net/21.15107/rcub_farfar_898 .